Background and Purpose: Intensity modulated radiation therapy (IMRT) combined treatment approaches, surgical and radiodiagnostic advances, respectively, lead to improved local-regional control in head neck cancer (HNC). With increasing local-regional control, distant metastases (DM) become more meaningful. In some trials without concomitant chemotherapy, induction chemotherapy (IC) resulted in an absolute reduction of DM by ~10-15%. In order to define a more efficient selection of patients at risk for DM with respect to IC and M-staging, we analysed our patients treated by contemporary standards. Patients and Methods: Between 1/2002 to 12/2007, 409 HNC patients were treated with IMRT; 303/409 (74%) underwent definitive, 106 (26%) postoperative IMRT. The mean/median follow-up was 23/20 months (3-72). 70% tolerated 4-7, 9% 1-3 cycles of simultaneous cisplatin. Treatment followed a prospectively designed protocol. In a previous study with 172 HNC IMRT patients, gross tumor volume (GTV) was found the strongest predictor for local-regional control. In the current study, this criterion has been prospectively tested for DM. Numbers needed to treat were calculated for IC. Results: DM developed in 28/399 (7%) patients; 10 presented initially with DM (total 38/409). In 13/28 (46%), DM remained the only manifestation of disease. GTV was the strongest predictor for DM (p < 0.0001) of all tested. Only 4% of patients with GTV < 70 cc developed DM, vs. 25% (18/73) with > 70 cc; only 6 of them (6/73, 8%) developed isolated DM. Conclusion: GTV was the most significant predictor for DM, that could guide selective pre-treatment M-staging. The subgroup with isolated DM in the high risk group, that could benefit from IC, is small. (Table 1) . Die Therapie folgte einem prospektiv festgelegten Protokoll. In einer früheren Studie mit 172 KHTPatienten mit definitiver IMRT wurde das "gross tumor volume" (GTV) als signifikantester Prädiktor für die Lokoregionalkontrolle nachgewiesen. In der hier präsentierten Studie wurde dasselbe volumetrische Staging-System getestet hinsichtlich dessen prä-diktiven Wert für DM, um eine allfällige IC wie auch die initiale Metastasensuche selektiver auf ein Hochrisikopatientensegment beschränken zu können. Ergebnisse: DM fanden sich bei 38/409 Patienten bzw. bei 28/399 mit initialem M0-Status (7%) (Abbildung 1, Tabelle 2); 10 Patienten hatten initial bereits DM. Bei nur 13/28 (46%) blieben DM die einzige Krankheitsmanifestation. Das GTV erwies sich als signifikantester aller getesteter Metastasenprädiktoren (p < 0,0001, Abbildung 2, Tabelle 3); nur 4% der Patienten mit einem GTV < 70 cc entwickelten DM, vs. 25% (18/73) mit GTV > 70 cc, von diesen nur 6 mit isolierter DM (6/73, 8%). 
Introduction
Clinical implementation of intensity modulated radiation therapy (IMRT), together with combined treatment approaches in definitive and postoperative treatment settings, surgical and radio-diagnostic advances, respectively, lead to an encouraging improvement of the loco-regional control in head and neck cancer (HNC) during the last years. When compared with the combined treatment arm of two prospective randomized trials from the near past with conventional irradiation (non IMRT), our IMRT cohort [26] showed an improvement of 3-year local-regional and overall survival rates of ~ 20% each (~ 70 vs. ~ 50%, and ~ 80 vs. ~ 60% [3, 14] respectively). This tendency results in a long term survivor population, for which distant metastasis (DM) may become more meaningful [30] .
In some trials, induction chemotherapy (IC) has shown to achieve an absolute reduction of DM of ~ 10-15% [1] , [Posner MJ: Educational book ASCO 2006]; IC is recently getting an issue of growing interest. However, its additional risks, mainly of limiting haematological reserves with respect to the following standard concomitant chemo-radiation, should not be underestimated. Risk prediction for DM could help to select and estimate the number of patients, who could benefit of IC.
A second point on which prediction of DM could have an impact on is pre-treatment search for metastasis. DM in HNC is a relatively rare event. Many patients with an a priori low probability for DM have to undergo staging examinations.
Aim of this study was to prospectively identify characteristics of HNC patients at high risk for DM, to achieve a more efficient selection of patients with respect to IC and M-staging. (Table 1 303/409 patients underwent definitive IMRT (dIMRT, 74%), 106 were referred for postoperative IMRT (pIMRT, 26%). Tumor sites were oropharynx (40%), oral cavity (19%), hypopharynx (15%), larynx (12%), nasopharynx (10%), and paranasal sinus (2%). The mean/median follow up time was 23/20 months (3-72). In 70% of all patients, 4-7 cycles of simultaneous cisplatin (40 mg/m 2 /w) were given, 9% tolerated 1-3 cycles. In 16%, no chemotherapy was added, mainly due to co-morbidity or age. In 22 patients (5%), concomitant ; n total = 172, in this recent study included), a volumetric staging system (VSS) was found the most important predictor of local-regional outcome [28] . This VSS bases on two cut-offs: primary or total gross tumor volume (GTV): 1-15 cc (favourable) vs. 16-70 cc (intermediate) vs. > 70 cc (unfavourable). While the primary GTV was used to predict local control rates, the total GTV was shown to best predict nodal control rates, disease free, and overall survival, respectively.
Patients
This volumetric criterion has since been applied prospectively in definitive IMRT patients (no GTV measurable in planning computed tomography [CT]) of operated patients), with respect to its predictive value for DM.
In addition, analyses taking the UICC (Union International Contre le Cancer) TNM criteria were performed, and the impact of treatment sequence, primary site, gender, and age as potential prognostic factors for DM, have been assessed. The recent study presents these results and its potential implications on clinical decisions.
All patients have been irradiated using IMRT with simultaneously integrated boost (SIB) technique [25] , using dIMRT schedules with 33 × 2.11 Gy to the boost planning target volume (boost PTV), or, -as a mild dose escalation -, with 33 × 2.2 Gy to large GTVs, or with 35 × 2.0 Gy to the boost PTV in patients with central nervous structures in the PTV, or with substantial parts of the larynx involved. The pIMRT schedule provided 30-33 × 2.0 Gy to the boost PTV. The elective dose was 54 Gy in most patients, intermediate doses of 60-66 Gy were delivered depending on individual risk.
All but 8 patients are in a regular follow up program in our HNC joint centre clinic or maxillofacial surgery clinic at the USZ. Routine tests included, besides the history, physical examination and endoscopy of the pharyngo-laryngeal region. If these tests were of no evidence of disease, usually no further tests were done but a CT scan or magnetic resonance imaging at 1 year post-treatment in the majority of patients.
Statistics
Survival data were calculated using Kaplan-Meier curves and log-rank tests implemented in StatView ® (Version 4.5). Proportions were compared using the Chi-square test. p values < 0.05 were considered statistically significant. Univariate and multivariate analyses were performed with a Cox proportional hazards regression model in StatView ® .
Results 3-year local and nodal control rates, disease free, and overall survival of the entire cohort were 80, 87, 73, and 80%, respectively. 74% of all patients were alive with no evidence of disease when last time seen.
A recent update of the definitive IMRT cohort using VSS shows 3-year local control rates of 93 vs. 78 vs. 50% for primary GTV 1-15 cc vs. 16-70 cc vs. > 70 cc, respectively (p < 0.0001); the corresponding disease free survival rates are 82 vs. 70 vs. 55% (p = 0.0002), the overall survival rates are 88 vs. 75 vs. 65% (p = 0.13).
Distant metastasis (DM, Figure 1 , Table 2 ) was diagnosed in 38 of all 409 patients (9%); 10/38 presented with initial DM, resulting in a DM rate of 7% (28/399) in initially M0 patients. 15/38 patients with DM died after mean/median 16/12 months (3-40) after completion of IMRT; mean/median survival time Predictive Factors for DM (Figure 2, Table 3 ) The pre-therapeutic GTV revealed to be the strongest predictive factor for DM in definitively irradiated patients with measurable primary or total GTV (p < 0.0001 each, (Figure 2 ) out of all assessed potentially predictive parameters. Only 9/230 patients (4%) with a total GTV < 70 cc developed DM, vs. 18/73 patients (25%) with total GVT > 70 cc. In uni-and multivariate analysis, the T-and N-systems were not significantly predicting the DM probability but in the constellation of localregionally advanced stages (≥ T3N2b) and N0-1 vs. N > 1 (Table 3) . Treatment sequence was not related to the DM rate (11/106 postoperative [10%] vs. 27/303 [9%] definitive IMRT patients). The site of primary was not a statistically significant predictor. DM was found in 6% of hypopharynx, 7% of oropharynx, 8% of oral cavity, 10% of nasopharyngeal cancer (NPC), and 14% of laryngeal tumors, respectively. Separate analyses showed no difference to the non-NPC cohort with respect to the DM rate (4/39 NPC [10%], 24/269 non-NPC [9%]; 3-y distant control 86% each). Age was not a significant factor neither, with mean 60.7 vs. 60.5 years in the DM vs. distantly controlled group.
All but one distant event occurred in men, however, 26% (61/236) of all male patients presented with a total GTV > 70 cc (i.e. 'at risk' for DM), while this was the case in only 12% (8/67) of females (p = 0.059, Chi-square proportion test). A retrospective analysis of the impact of cisplatin on DM showed no difference between patients with no chemotherapy vs the ones with 1-3 vs. 4-7 cycles, however, this is of limited value, as the subgroup with no or few cycles of cisplatin is characterized by elderly or co-morbid patients. 14% of patients (59/409) were diagnosed for a second or even third or forth primary prior or following IMRT, 4 of them belonged to the DM subgroup.
Discussion
The observed low DM incidence rate of 7% (28/399 patients with initial M0-status, (Figure 1 ) is concordant with that of recent reports in the IMRT literature, ranging between ~ 8-12% (> 90% 3y DM-free survival) [4, 6, 19, 30] following IMRT-chemotherapy, and seems to be lower than many published values following conventional radiation techniques, with ~ 8-25% of DM [1, 2, 3, 8, 11, 14, 24] . A relation between increasing localregional tumor control rates following IMRT and this tendency to decreasing DM rates can not be excluded.
Associations between various factors like primary site, regional extension (TN-stage), grading and others, and the rate of DM have been reported [2, 12, 15, 20, 23, 24, 30] .
In our cohort, GTV was the strongest statistically significant predictor for DM (Table 3) . Tumor volume has formerly been reported as a statistically significant factor for DM in HNC by Chao et al. [4] (as well as for other tumors [29] ). As far as we know, the here presented study is the first attempt to use a VSS with defined predictive cut off values for DM prediction. The tested VSS has been reported as a highly reliable tool to predict local-regional outcome [28] , and could herewith been confirmed as similarly reliable in predicting DM (Figure 2 ).
Our N0-1 vs. N > 1 nodal subgroups showed a less strong but significant difference in predicting DM (p = 0.04), while N-status itself was not significant (yet), likely due to the small number of events per N-stage, and maybe also due to the fact that not all lymph nodes considered as 'tumor affected' have been histopathologically confirmed. Even if the difference was statistically significant, the percentage difference of DM was low (5 vs. 12%, (Table 3) , and therefore this criterion not too helpful as prognostic selection tool. Similarly, the combination of advanced TN stages resulted in a ratio of only 14% vs. 7% DM. The 'risky' constellation 'tGTV > 70 cc plus advanced N status ≥ N2b' revealed to be equal to the constellation 'tGTV > 70 cc plus early N status < N2b', compared to 'tGTV < 70 cc plus any N' (23 and 20 vs. 4% DM), showing the superiority of the volumetric over the nodal criterion (Table 3, grey field).
The site of the primary may influence the rate of DM, with reported ~ 75-80% 2-3y DM-free survival rates in localregionally advanced nasopharyngeal [16, 18, 21, 29] , sinonasal [9, 13, 22] , hypopharyngeal [27] and laryngeal tumors [5] , ~ 85-95% in oropharyngeal tumors [4, 7, 15] , and ~ 90-95% in oral cavity cancer (OCC) [3] [4] [5] [6] 10] , respectively. For local-regionally advanced hypopharyngeal tumors, 3y-DM free survival rates of as low as 30% are reported [8, 17] . Comparisons of DM rates between the studies are difficult due to a wide range of treatment approaches, staging examinations, and treatments. In our population, no significant primary site related difference was found, likely due to imbalanced samples with low numbers of events per entity; with respect to the equal DM rate in NPC and non-NPC, one has to consider the different treatment, with additional post-radiochemotherapeutic chemotherapy (cisplatin/5-FU) in NPC, according to the standard.
All but one patient with DM were men. However, considering that 62/236 dIMRT treated male patients presented with a tumor volume > 70 cc (26%), while this was the case in only 8/67 women (12%, i.e. 2-times less large tumors in women), this has to be taken with caution.
Potential Consequences of Volumetric DM Prediction
One quarter of patients with GTV > 70 cc presented with DM at diagnosis or during the first 12 months from treatment start, while only 4% with GTV < 70 cc. Volumetric staging may serve as selection tool to detect high risk patients for DM with respect to the question of IC. In some randomised earlier trials, adjuvant chemotherapy in patients with locally advanced HNC showed a reduction of DM from ~ 25-15%, a relative reduction of approximately 40%. We consider this observation as helpful information in discussing IC.
For various subgroups at risk, the number needed to treat (NNT) has been calculated (Table 4) : the NNT was lowest for the volumetric criterion (factor 1.5 to ~ 3), the absolute number of patients who may profit from IC is small. 
There is still a certain probability that IC could also be loco-regionally effective, however, hardly by a similar factor than concomitant radio-chemotherapy is.
With respect to pre-therapeutic M-staging with PET(CT), VSS would similarly allow to narrow DM search to a subgroup of high risk for DM. Considering that findings of 'small/limited/suspected' DM at diagnosis do often not change our localregional treatment approach (i.e., patients with initially diagnosed limited DM and local-regionally disease considered as 'curable', underwent IMRT with 'local-regionally curative' intention), one could even provide to confine M-staging to the few patients with local-regionally as 'hardly curable' stated disease, in order to use PETCT to ease the decision for palliative treatment.
VSS may therefore translate into therapeutic and/or diagnostic consequences.
Conclusion
GTV was the most significant predictor for DM, revealing DM in one quarter of patients with GTV > 70 cc vs. < 5% in patients with GTV < 70 cc, respectively. These finding could translate into a more rationale and selective pre-treatment M staging, and consideration of induction chemotherapy confined to patients at high risk. These are the same patients who could benefit from an improvement of local-regional control. However, even in the DM high risk group, the subgroup with isolated DM, that could benefit from IC, is small.
